https://flcube.com/?p=14855
Hanx Biopharmaceuticals' HX009 Receives NMPA Clinical Trial Approval for PD-1/CD47 Bispecific...
Nov 25, 2024 - China-based Hanx Biopharmaceuticals Co., Ltd has announced that its self-developed anti PD-1/CD47 bispecific antibody drug, HX009, has received a clinical...
clinical trialhanxbiopharmaceuticalsreceivesnmpa